Novo NordiskSee all their emails

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

A real announcement email from Novo Nordisk. Captured June 11, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces the UK regulatory approval of Wegovy pill, a new daily oral GLP-1 treatment for weight management.

A formal press release layout with a top-aligned company logo, followed by a bulleted summary, detailed body text, quotes, trial data, and a structured contact information table at the bottom.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.